SUBCUTANEOUS INOCULATION OF ALLOGENEIC GENE-MODIFIED TUMOR CELLS ACHN-IL2 MIXED TO AUTOLOGOUS TUMOR CELLS CT-AUT IN PATIENTS WITH METASTATIC RENAL CARCINOMA. - ND

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-001504-37-IT

Enrollment

200

Registered

2006-06-23

Start date

2006-05-18

Completion date

Unknown

Last updated

2016-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Kidney Cancer MedDRA version: 6.1 Level: PT Classification code 10050018

Interventions

Product Name: ACHN-IL2 Pharmaceutical Form: Suspension for injection Current Sponsor code: ACHN-IL2 Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 1000000

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 documented Diagnosis of metastatic renal carcinoma; 2 Performance status Karnofsky 80-100 and one prognosis quoad vitam advanced to 4 months; Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1 Performance status Karnofsky 80-100 and one prognosis quoad vitam inferior to 4 months;

Design outcomes

Primary

Measure	Time frame
Main Objective: appraisal of the survival and quality of the life;Secondary Objective: clinical regression of the lesions;Primary end point(s): appraisal of the survival	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026